SG Americas Securities
STML

SG Americas Securities’s Stemline Therapeutics, Inc. STML Stock Holding History

SG Americas Securities’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-6,818
Closed -$104K – 3352
2019
Q2 		$104K Buy
+6,818
New +$98.6K ﹤0.01% 2793
2013
Q4 		– Sell
-2,292
Closed -$104K – 3160
2013
Q3 		$104K Buy
+2,292
New +$74.8K ﹤0.01% 2641

Other funds holding STML

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

SG Americas Securities's STML Position: Q3 2019 in Review

SG Americas Securities sold out of Stemline Therapeutics, Inc. (STML) in Q3 2019, closing a stake of 6,818 shares — an estimated $104K sold.

SG Americas Securities first reported a position in STML in Q3 2013 and held it in 2 quarters. The position peaked at $104K in Q2 2019. 100 funds tracked by Wall St. Rank hold STML as of Q3 2019.

  • SG Americas Securities reported no remaining Stemline Therapeutics, Inc. position as of Q3 2019 after selling out during the quarter.
  • SG Americas Securities sold 6,818 Stemline Therapeutics, Inc. shares in Q3 2019, an estimated $104K.
  • SG Americas Securities first reported a position in Stemline Therapeutics, Inc. in Q3 2013 and held it in 2 quarters.
  • SG Americas Securities's Stemline Therapeutics, Inc. position peaked at $104K in Q2 2019.
  • 100 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q3 2019.

Based on SG Americas Securities's 13F filing for Q3 2019, filed 4 Nov 2019.